Authors
Latest:
Dr. Cmelak Discusses the Results of the ECOG1308 StudyAnthony J. Cmelak, MD, professor, Radiation Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of ECOG1308, a study that evaluated reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response to induction chemotherapy.
Latest:
Dr. Olszanski Discusses Advances in Stage III MelanomaAnthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.
Latest:
Dr. Magliocco on Analyzing the Genome of Melanoma TumorsAnthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.
Latest:
Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLLAnthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.
Latest:
The Future of the Treatment Landscape in MZL and FLKey opinion leaders in hematology-oncology consider the future treatment landscape for marginal zone and follicular lymphomas and reflect on the role of chemotherapy and targeted agents as induction or maintenance.
Latest:
Noncovalent BTK Inhibitors in CLLRecommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
Latest:
Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLLLooking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
Latest:
Dr. Stein on Blinatumomab for Relapsed/Refractory ALLAnthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Latest:
Dr. Shields on the Standard of Care in Newly Diagnosed mCRCAnthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).
Latest:
Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid TumorsAnthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.
Latest:
Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLCAntoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.
Latest:
Melanoma: Improving Clinical Outcomes Through Advances in Immunotherapeutics and Targeted TherapyMetastatic melanoma has limited treatment options, but advances in the understanding of the oncogenic mutations that drive this cancer and how the immune system can be better modulated to fight melanoma provide a new generation of active approaches for patients.
Latest:
Dr. Ribas on Immune-Related Adverse Events in MelanomaAntoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.
Latest:
Dr. Wolff Discusses the Importance of HER2 TestingDr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing
Latest:
Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian CancerAntonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.
Latest:
Dr. Iavarone on the Role of the ID2 Protein in Brain CancerAntonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Latest:
Dr Llombart-Cussac on the Implications of Prophylaxis for Neutropenia and Diarrhea in Advanced Breast CancerAntonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.
Latest:
Dr. Palumbo on Significance of Daratumumab Triplet in Multiple MyelomaAntonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.
Latest:
Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLCAntonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.
Latest:
Potential Molecular Markers in Liver CancerAnuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.
Latest:
Dr. Ganti on Lung Cancer Abstracts From the 2018 ASCO Annual MeetingApar Kishor Ganti, MD, professor of internal medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, discusses lung cancer abstracts that were presented at the 2018 ASCO Annual Meeting.
Latest:
Dr Parikh on Available Treatment Options for HER2+ CRCAparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.
Latest:
Dr. Tsimberidou on the Impact Trial in Patients With Advanced CancerApostolia Maria Tsimberidou, MD, PhD, tenured professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the IMPACT trial in patients with advanced cancer.
